Sanofi
Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof
Last updated:
Abstract:
The invention provides antibodies that specifically bind to Plasminogen Activator inhibitor type-1 (PAI-1). The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAT-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAT-1 in the active conformational state.
Status:
Application
Type:
Utility
Filling date:
6 Aug 2019
Issue date:
28 Nov 2019